USPTO serial 97833606
RXACADEMY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 23, 2024
- Examiner
- RUSKIN, MATTHEW SEAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RXACADEMY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Steven M. Espenshade
Steven M. Espenshade PIRKEY BARBER PLLC1801 EAST 6TH STREET, SUITE 300AUSTIN, TX 78702UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 041 | Providing on-line training courses in the field of injectable and infusion health care services and pharmacy; providing on-line courses of instruction in the field of injectable and infusion health care services and pharmacy; educational services, namely, providing on-line courses of instruction in the fields of medicine, medical care, medical procedures, health care, office-administered medications, injectable and infusion health care services; providing training for certification in the field of pharmacy and health care services; educational services, namely, conducting exam preparation courses in the field of pharmacy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 23, 2024 | NRCS | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 23, 2024 | R.SR | REGISTERED-SUPPLEMENTAL REGISTER | Your mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application. |
| Mar 20, 2024 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| Mar 17, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 17, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 17, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 18, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 31, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 14, 2023 | NWAP | NEW APPLICATION ENTERED | — |